A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

被引：2
|
作者：
Reagan, Patrick M.
Portell, Craig A.
Casulo, Carla
Baran, Andrea M.
Magnuson, Allison
Barr, Paul M.
Lerman, Yelena
French, Krista N.
Friedberg, Jonathan W.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140384
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
    Bartlett, Nancy L.
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua, Juan-Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    Macdonald, David
    Portell, Craig A.
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Yasenchak, Christopher A.
    Patterson, Monica
    Ho, Linda
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Kim, Jeong-A
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [2] Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).
    Bartlett, Nancy L.
    Yasenchak, Christopher A.
    Ashraf, Khaleel K.
    Harwin, William N.
    Sims, Robert Brownell
    Nowakowski, Grzegorz S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
    Ward, Jeffrey P.
    Berrien-Elliott, Melissa M.
    Gomez, Felicia
    Luo, Jingqin
    Becker-Hapak, Michelle
    Cashen, Amanda F.
    Wagner-Johnston, Nina D.
    Maddocks, Kami
    Mosior, Matthew
    Foster, Mark
    Krysiak, Kilannin
    Schmidt, Alina
    Skidmore, Zachary L.
    Desai, Sweta
    Watkins, Marcus P.
    Fischer, Anne
    Griffith, Malachi
    Griffith, Obi L.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2022, 139 (13) : 1999 - 2010
  • [4] Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis
    Sato, Shuku
    Tsunoda, Shun
    Kamata, Wataru
    Togano, Tomiteru
    Tamai, Yotaro
    BLOOD RESEARCH, 2025, 60 (01)
  • [5] Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Bartlett, Nancy L.
    Yasenchak, Christopher A.
    Sims, Robert B.
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
  • [6] PHARMACOKINETICS OF RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Rozman, S.
    Grabnar, I.
    Novakovic, S.
    Mrhar, A.
    Novakovic, B. Jezersek
    HAEMATOLOGICA, 2017, 102 : 688 - 688
  • [7] IMPACT OF DOSE INTENSITY IN OLDER PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
    Warley, Fernando
    Kalmus, Mariana
    Cristaldo, Nancy
    Ismael, Ileana l.
    Boietti, Bruno
    Smietniansky, Maximiliano
    MEDICINA-BUENOS AIRES, 2023, 83 (05) : 854 - 856
  • [8] Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)
    Bartlett, Nancy L.
    Yasenchak, Christopher A.
    Ashraf, Khaleel
    Harwin, William
    Sims, Robert
    Nowakowski, Grzegorz S.
    BLOOD, 2021, 138
  • [9] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
    Tilly, H.
    Sharman, J.
    Bartlett, N.
    Morschhauser, F.
    Haioun, C.
    Munoz, J.
    Chen, A.
    Lamy, T.
    Wang, L.
    Penuel, E.
    Hirata, J.
    Lee, C.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 4 - 4
  • [10] Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study
    Kim, Jeong A.
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Burgues, Juan Miguel Bergua
    Bouabdallah, Krimo
    Forward, Nick
    Bijou, Fontanet
    MacDonald, David
    Portell, Craig Anthony
    Ghesquieres, Herve
    Nowakowski, Grzegorz S.
    Yasenchak, Christopher A.
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Bartlett, Nancy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA7005 - LBA7005
12345